Is it Time to Dump Humanigen Inc (HGEN) Stock After it Has Fallen 6.25% in a Week?

Thursday, March 02, 2023 10:57 AM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump Humanigen Inc (HGEN) Stock After it Has Fallen 6.25% in a Week?

The market has been down on Humanigen Inc (HGEN) stock recently. HGEN gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Humanigen Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on HGEN!

See Full HGEN Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With HGEN Stock Today?

Humanigen Inc (HGEN) stock is higher by 13.13% while the S&P 500 is down -0.12% as of 10:50 AM on Thursday, Mar 2. HGEN has risen $0.02 from the previous closing price of $0.13 on volume of 3,312,175 shares. Over the past year the S&P 500 is down -8.35% while HGEN is down -93.53%. HGEN lost -$1.52 per share in the over the last 12 months.

More About Humanigen Inc

Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. Click Here to get the full Stock Report for Humanigen Inc stock.